Nearly a hundred individual stocks were surveyed by institutions in the past week, with Guoxin Health having the highest number of institutional surveys.

Nearly a hundred individual stocks were surveyed by institutions over the past week, with Guoxin Health having the highest number of institutional surveys. Guoxin Health was surveyed by 139 institutions, including 31 securities firms, 47 private equity firms, and 10 insurance companies. During the survey, an institution asked what the core reason was for the rapid revenue growth in the company's health services business in the semi-annual report. Guoxin Health stated that it was mainly due to the continued advancement of chronic disease management and health management businesses. In the health services sector, leveraging its long-term accumulation in the three medical fields, the company continues to improve its chronic disease management service system, strengthen supply guarantees, platform support, and intelligent service capabilities, and actively promotes the integration of AI technology with health service scenarios to enhance service efficiency and user experience. Currently, the company's chronic disease management business in the Shandong region continues to advance, and it will continue to do a good job in the refined operation of existing projects and the improvement of service capabilities. Fuxiang Co., Ltd., Bojie Co., Ltd., Huabao Co., Ltd., and others whose performance surged sharply recently received institutional surveys. From the perspective of market performance, institutional survey stocks rose by an average of 0.27% over the past week, with Huning Co., Ltd., Yitian Smart, Changlan Technology, and other individual stocks leading the gains.